Demographic, molecular, and clinical features of pRD patients
| Patient # | Sex | Age at the time of the study | Gene defect | Allele 1; Allele 2 | Infections | Immune dysregulation | Other complications | Treatment of immune dysregulation | BMT and outcome |
|---|---|---|---|---|---|---|---|---|---|
| P1 | F | 37 years | RAG1 | p.C176F; p.C176F | Norovirus, URTI, LRTI, Pseudomonas pneumonia, bronchiectasis, Salmonella gastroenteritis, PJP | IBD, hypothyroidism | Hepatomegaly with bridging fibrosis and steatosis | Steroids | Yes, deceased |
| P2 | M | 16 mo | RAG1 | p.A444V; p.V869F | URTI, LRTI, Aspergillus pneumonia, Stenotrophomonas maltophilia, Citrobacter freundii, adenovirus and norovirus gastroenteritis, Helicobacter pylori | VEOIBD, AIHA | Exocrine pancreatic insufficiency, cholestatic hepatitis | Steroids | Yes, A&W after 1 year |
| P3 | M | 8 years | RAG1 | p.R112H; p.R112H | RTI | IBD | Ustekinumab | No, alive with IBD | |
| P4 | M | 25 mo | RAG1 | p.C176F; p.C176F | Recurrent bacterial and viral URTI, severe CMV viremia | VEOIBD with hematochezia and hematemesis | Tacrolimus | Yes, deceased | |
| P5 | M | 11 years | RAG1 | p.P152L; p.R973C | RTI, bronchiectasis | IBD, Evans syndrome | Steroids | Yes, A&W after 1 year | |
| P6 | M | 32 years | RAG2 | p.G451A; p.G451A | COVID-19, CMV, rubella | Liver fibrosis | No, deceased | ||
| P7 | F | 44 years | RAG1 | p.R474C; p.R474C | Genital HPV and HSV, URTI, LRTI, bronchiectasis, Pseudomonas, pneumonia, MAC, Nocardia lung infection | Panarteritis nodosa, T1DM, hypothyroidism, pernicious anemia, arthritis, granulomas | Granulosa cell ovarian cancer | Etanercept, methotrexate | Yes, deceased |
| P8 | F | 6 years | RAG1 | p.R112H; p.C328Y | Recurrent pneumonia, bronchiectasis, diarrhea | AIHA | Steroids | Yes, A&W after 5 years | |
| P9 | F | 35 years | RAG1 | p.W522C; p.R975Q | Recurrent HSV, URTI, LRTI, bronchiectasis, onychomycosis | Alopecia, vitiligo, arthritis, asthma | Ovarian insufficiency | Hydroxychloroquine | Yes, A&W after 3 years |
| P10 | M | 12 years | RAG1 | p.Y562C; p.R841Q | URTI, LRTI, bronchiectasis, mastoiditis | AIHA, hypothyroidism, splenomegaly | Steroids | Yes, deceased | |
| P11 | M | 3 years | RAG1 | p.K86Vfs*33; p.C328Y | EBV viremia | Rituximab | Yes, deceased | ||
| P12 | M | 23 years | RAG1 | p.R410W; p.R507Q | Warts, EBV viremia, URTI, LRTI | Vitiligo, alopecia, granulomas | Etanercept, adalimumab, hydroxychloroquine | Yes, A&W after 5 years | |
| P13 | M | 39 years | RAG1 | p.R108*; p.W522C | Warts, orolabial HSV, LRTI, bronchiectasis, MRSA, oral candidiasis | Alopecia, hypothyroidism, hypogonadism, granulomas | Steroids, MMF, rituximab | Yes, A&W after 6 years | |
| P14 | M | 7 years | RAG1 | p.G393V; p.G709A | URTI, LRTI, perianal abscess | Autoimmune hypothyroidism | Yes, A&W after 2 years | ||
| P15 | F | 12 years | RAG1 | p.R404W; p.H747P | Herpes labialis, HSV keratitis, LRTI, septic shock, ecthyma gangrenosum | AIHA | MMF, rituximab, sirolimus | Yes, A&W after 5 years | |
| P16 | M | 18 years | RAG1 | p.K86Vfs*33; p.H612R | Chronic sinusitis, recurrent LRTI, bronchiectasis, COVID-19 | AIHA, thyroiditis, vitiligo | Steroids | Yes, A&W after 21 mo |
| Patient # | Sex | Age at the time of the study | Gene defect | Allele 1; Allele 2 | Infections | Immune dysregulation | Other complications | Treatment of immune dysregulation | BMT and outcome |
|---|---|---|---|---|---|---|---|---|---|
| P1 | F | 37 years | p.C176F; p.C176F | Norovirus, URTI, LRTI, | IBD, hypothyroidism | Hepatomegaly with bridging fibrosis and steatosis | Steroids | Yes, deceased | |
| P2 | M | 16 mo | p.A444V; p.V869F | URTI, LRTI, Aspergillus pneumonia, | VEOIBD, AIHA | Exocrine pancreatic insufficiency, cholestatic hepatitis | Steroids | Yes, A&W after 1 year | |
| P3 | M | 8 years | p.R112H; p.R112H | RTI | IBD | Ustekinumab | No, alive with IBD | ||
| P4 | M | 25 mo | p.C176F; p.C176F | Recurrent bacterial and viral URTI, severe CMV viremia | VEOIBD with hematochezia and hematemesis | Tacrolimus | Yes, deceased | ||
| P5 | M | 11 years | p.P152L; p.R973C | RTI, bronchiectasis | IBD, Evans syndrome | Steroids | Yes, A&W after 1 year | ||
| P6 | M | 32 years | p.G451A; p.G451A | COVID-19, CMV, rubella | Liver fibrosis | No, deceased | |||
| P7 | F | 44 years | p.R474C; p.R474C | Genital HPV and HSV, URTI, LRTI, bronchiectasis, | Panarteritis nodosa, T1DM, hypothyroidism, pernicious anemia, arthritis, granulomas | Granulosa cell ovarian cancer | Etanercept, methotrexate | Yes, deceased | |
| P8 | F | 6 years | p.R112H; p.C328Y | Recurrent pneumonia, bronchiectasis, diarrhea | AIHA | Steroids | Yes, A&W after 5 years | ||
| P9 | F | 35 years | p.W522C; p.R975Q | Recurrent HSV, URTI, LRTI, bronchiectasis, onychomycosis | Alopecia, vitiligo, arthritis, asthma | Ovarian insufficiency | Hydroxychloroquine | Yes, A&W after 3 years | |
| P10 | M | 12 years | p.Y562C; p.R841Q | URTI, LRTI, bronchiectasis, mastoiditis | AIHA, hypothyroidism, splenomegaly | Steroids | Yes, deceased | ||
| P11 | M | 3 years | p.K86Vfs*33; p.C328Y | EBV viremia | Rituximab | Yes, deceased | |||
| P12 | M | 23 years | p.R410W; p.R507Q | Warts, EBV viremia, URTI, LRTI | Vitiligo, alopecia, granulomas | Etanercept, adalimumab, hydroxychloroquine | Yes, A&W after 5 years | ||
| P13 | M | 39 years | p.R108*; p.W522C | Warts, orolabial HSV, LRTI, bronchiectasis, MRSA, oral candidiasis | Alopecia, hypothyroidism, hypogonadism, granulomas | Steroids, MMF, rituximab | Yes, A&W after 6 years | ||
| P14 | M | 7 years | p.G393V; p.G709A | URTI, LRTI, perianal abscess | Autoimmune hypothyroidism | Yes, A&W after 2 years | |||
| P15 | F | 12 years | p.R404W; p.H747P | Herpes labialis, HSV keratitis, LRTI, septic shock, ecthyma gangrenosum | AIHA | MMF, rituximab, sirolimus | Yes, A&W after 5 years | ||
| P16 | M | 18 years | p.K86Vfs*33; p.H612R | Chronic sinusitis, recurrent LRTI, bronchiectasis, COVID-19 | AIHA, thyroiditis, vitiligo | Steroids | Yes, A&W after 21 mo |
AIHA, autoimmune hemolytic anemia; A&W, alive and well; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HPV, human papillomavirus; HSV, herpes simplex virus; IBD, inflammatory bowel disease; LRTI, lower respiratory tract infections; MAC, Mycobacterium avium complex; MMF, mycophenolate mofetil; MRSA, methicillin-resistant Staphylococcus aureus; PJP, Pneumocystis jirovecii pneumonia; RTI, respiratory tract infections; T1DM, type 1 diabetes mellitus; URTI, upper respiratory tract infections; VEOIBD, very early-onset inflammatory bowel disease.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.